Skip to main content
SpringerLink
Log in

Role of Estrogen and Progesterone in Obesity Associated Gynecologic Cancers

For Publication in Energy Balance and Gynecologic Cancers

  • Chapter
  • First Online:
Focus on Gynecologic Malignancies

Part of the book series: Energy Balance and Cancer ((EBAC,volume 13))

Abstract

Obesity is an established endometrial cancer risk factor, and may, to a lesser extent, also increase ovarian cancer. Given that the primary source of postmenopausal estrogens is through peripheral conversion of precursors in adipose tissue and that endometrial cancer arises from an imbalance of estrogen to progesterone levels, much attention has focused on these two hormones.

Indirect evidence for an important role of these hormones derives from studies of menopausal hormones and oral contraceptives, whose use is, respectively, directly and inversely associated with both endometrial and ovarian cancer risks. Endometrial cancer risks are particularly enhanced if unopposed estrogens are prescribed, especially among thin women.

Studies have demonstrated a link between high endogenous estrogen levels and increased endometrial cancer risk, with most metabolites showing evidence of uterotropic activity. Estrogens are less strongly related to ovarian cancer, although may predispose some to non-serous cancers, which are also enhanced among obese women.

Difficulties in measuring progesterone levels have hampered our understanding of their effects, although improved assays have recently been developed. To fully understand the role of estrogens and progestogens, additional attention should focus on other hormones (e.g., androgens), insulin, growth factors, and such obesity-related biomarkers as adiponectin.

While cervical and vulvar cancers do not show strong relations of risk with obesity, it is possible that hormonal changes associated with obesity may enhance the effects of the human papillomaviruses, important causes of both of these tumors.

With obesity rates rapidly increasing, further clarification of the biologic underpinnings of gynecologic cancers are needed to inform future prevention efforts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society: Cancer Facts & Figures 2015, 2015.

    Google Scholar 

  2. Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205:518–25.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.

    Article  PubMed  Google Scholar 

  4. Sponholtz TR, Palmer JR, Rosenberg L, et al. Body size, metabolic factors, and risk of endometrial cancer in black women. Am J Epidemiol. 2016;183:259–68.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Upala S, Anawin S. Bariatric surgery and risk of postoperative endometrial cancer: a systematic review and meta-analysis. Surg Obes Relat Dis. 2015;11:949–55.

    Article  PubMed  Google Scholar 

  6. Nagle CM, Marquart L, Bain CJ, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer. 2013;49:2717–26.

    Article  CAS  PubMed  Google Scholar 

  7. Linkov F, Maxwell GL, Felix AS, et al. Longitudinal evaluation of cancer-associated biomarkers before and after weight loss in RENEW study participants: implications for cancer risk reduction. Gynecol Oncol. 2012;125:114–9.

    Article  PubMed  Google Scholar 

  8. Dougan MM, Hankinson SE, Vivo ID, et al. Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. Int J Cancer. 2015;137:625–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Friedenreich C, Cust A, Lahmann PH, et al. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2007;18:399–413.

    Article  PubMed  Google Scholar 

  10. Ju W, Kim HJ, Hankinson SE, et al. Prospective study of body fat distribution and the risk of endometrial cancer. Cancer Epidemiol. 2015;39:567–70.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Schmid D, Behrens G, Keimling M, et al. A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol. 2015;30:397–412.

    Article  CAS  PubMed  Google Scholar 

  12. Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure-Time Physical Activity with Risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 2016;176:816–25.

    Article  PubMed  Google Scholar 

  13. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhao S, Chlebowski RT, Anderson GL, et al. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res. 2014;16:R30.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45:277–82.

    CAS  PubMed  Google Scholar 

  16. Fearnley EJ, Marquart L, Spurdle AB, et al. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010;21:2303–8.

    Article  PubMed  Google Scholar 

  17. Gottschau M, Kjaer SK, Jensen A, et al. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015;136:99–103.

    Article  PubMed  Google Scholar 

  18. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327–31.

    Article  PubMed  Google Scholar 

  19. Pandey A, Forte V, Abdallah M, et al. Diabetes mellitus and the risk of cancer. Minerva Endocrinol. 2011;36:187–209.

    CAS  PubMed  Google Scholar 

  20. Sheikh MA, Althouse AD, Freese KE, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol. 2014;10:2561–8.

    Article  CAS  PubMed  Google Scholar 

  21. Collaborative Group on Epidemiological Studies on Endometrial C. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061–70.

    Article  Google Scholar 

  22. Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535–40.

    Article  CAS  PubMed  Google Scholar 

  23. Felix AS, Gaudet MM, La Vecchia C, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the epidemiology of endometrial cancer consortium. Int J Cancer. 2015;136:E410–22.

    Article  CAS  PubMed  Google Scholar 

  24. Beral V, Bull D, Reeves G, et al. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet. 2005;365:1543–51.

    Article  PubMed  Google Scholar 

  25. Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous combined estrogen plus progestin and endometrial cancer: the Women's Health Initiative randomized trial. J Natl Cancer Inst. 2016;108

    Google Scholar 

  26. Razavi P, Pike MC, Horn-Ross PL, et al. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomark Prev. 2010;19:475–83.

    Article  CAS  Google Scholar 

  27. Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer. 2013;132:417–26.

    Article  CAS  PubMed  Google Scholar 

  28. Yang TY, Cairns BJ, Allen N, et al. Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. Br J Cancer. 2012;107:169–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sjogren LL, Morch LS, Lokkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas. 2016;91:25–35.

    Article  CAS  PubMed  Google Scholar 

  30. Morch LS, Lokkegaard E, Andreasen AH, et al. Hormone therapy and ovarian cancer. JAMA. 2009;302:298–305.

    Article  PubMed  Google Scholar 

  31. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a gynecologic oncology group trial. Gynecol Oncol. 2013;129:277–84.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kamal A, Tempest N, Parkes C, et al. Hormones and endometrial carcinogenesis. Horm Mol Biol Clin Investig. 2016;25:129–48.

    CAS  PubMed  Google Scholar 

  34. Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin Pharmacother. 2009;10:2209–20.

    Article  CAS  PubMed  Google Scholar 

  35. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev. 2002;11:1531–43.

    CAS  Google Scholar 

  36. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids. 2015;99:8–10.

    Article  CAS  PubMed  Google Scholar 

  37. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108:425–32.

    Article  CAS  PubMed  Google Scholar 

  38. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer. 2008;15:485–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev. 2008;17:921–9.

    Article  CAS  Google Scholar 

  40. Ziegler RG, Fuhrman BJ, Moore SC, et al. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 2015;99:67–75.

    Article  CAS  PubMed  Google Scholar 

  41. Dallal CM, Tice JA, Buist DS, et al. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. Carcinogenesis. 2014;35:346–55.

    Article  CAS  PubMed  Google Scholar 

  42. Fuhrman BJ, Schairer C, Gail MH, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012;104:326–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Zeleniuch-Jacquotte A, Shore RE, Afanasyeva Y, et al. Postmenopausal circulating levels of 2- and 16alpha-hydroxyestrone and risk of endometrial cancer. Br J Cancer. 2011;105:1458–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Dallal CM, Lacey JV Jr, Pfeiffer RM, et al. Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B approximately FIT cohort. Horm Cancer. 2016;7:49–64.

    Article  CAS  PubMed  Google Scholar 

  45. Audet-Walsh E, Lepine J, Gregoire J, et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab. 2011;96:E330–9.

    Article  CAS  PubMed  Google Scholar 

  46. Zhao H, Jiang Y, Liu Y, et al. Endogenous estrogen metabolites as biomarkers for endometrial cancer via a novel method of liquid chromatography-mass spectrometry with hollow fiber liquid-phase microextraction. Horm Metab Res. 2015;47:158–64.

    CAS  PubMed  Google Scholar 

  47. Brinton LA, Trabert B, Anderson GL, et al. Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiol Biomark Prev. 2016;25:1081–9.

    Article  CAS  Google Scholar 

  48. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res. 2000;60:235–7.

    CAS  PubMed  Google Scholar 

  49. Reddy VV, Hanjani P, Rajan R. Synthesis of catechol estrogens by human uterus and leiomyoma. Steroids. 1981;37:195–203.

    Article  CAS  PubMed  Google Scholar 

  50. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1–27.

    Article  PubMed  Google Scholar 

  51. Takahashi M, Shimomoto T, Miyajima K, et al. Effects of estrogens and metabolites on endometrial carcinogenesis in young adult mice initiated with N-ethyl-N'-nitro-N-nitrosoguanidine. Cancer Lett. 2004;211:1–9.

    Article  CAS  PubMed  Google Scholar 

  52. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31:2607–18.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Yang HP, Wentzensen N, Trabert B, et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP diet and health study. Am J Epidemiol. 2013;177:142–51.

    Article  PubMed  Google Scholar 

  54. Morch LS, Kjaer SK, Keiding N, et al. The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study. Int J Cancer. 2016;138:1506–15.

    Article  CAS  PubMed  Google Scholar 

  55. Ashihara K, Tanaka T, Maruoka R, et al. Postmenopausal patients with endometrial cancer of type 1 have elevated serum estradiol levels in the ovarian vein. Int J Gynecol Cancer. 2014;24:1455–60.

    Article  PubMed  Google Scholar 

  56. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308.

    Article  CAS  PubMed  Google Scholar 

  57. Armstrong AJ, Hurd WW, Elguero S, et al. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012;19:562–71.

    Article  PubMed  Google Scholar 

  58. Trabert B, Falk RT, Stanczyk FZ, et al. Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatography-tandem mass spectrometry. Horm Mol Biol Clin Investig. 2015;23:79–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Zheng Q, Wu H, Cao J. Circulating adiponectin and risk of endometrial cancer. PLoS One. 2015;10:e0129824.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Dossus L, Lukanova A, Rinaldi S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort--a factor analysis. Am J Epidemiol. 2013;177:787–99.

    Article  PubMed  Google Scholar 

  61. Brons N, Baandrup L, Dehlendorff C, et al. Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case-control study. Cancer Causes Control. 2015;26:973–81.

    Article  PubMed  Google Scholar 

  62. Friedenreich CM, Langley AR, Speidel TP, et al. Case-control study of inflammatory markers and the risk of endometrial cancer. Eur J Cancer Prev. 2013;22:374–9.

    Article  CAS  PubMed  Google Scholar 

  63. Cust AE, Allen NE, Rinaldi S, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;120:2656–64.

    Article  CAS  PubMed  Google Scholar 

  64. Hernandez AV, Pasupuleti V, Benites-Zapata VA, et al. Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2015;51:2747–58.

    Article  CAS  PubMed  Google Scholar 

  65. Collaborative Group on Epidemiological Studies of Ovarian C. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9:e1001200.

    Article  Google Scholar 

  66. Olsen CM, Nagle CM, Whiteman DC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the ovarian cancer association consortium. Endocr Relat Cancer. 2013;20:251–62.

    Article  PubMed  Google Scholar 

  67. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer. 2012;131:938–48.

    Article  CAS  PubMed  Google Scholar 

  68. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–14.

    Article  Google Scholar 

  69. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003;290:1739–48.

    Article  CAS  PubMed  Google Scholar 

  70. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online. 2002;4:303–10.

    Article  CAS  PubMed  Google Scholar 

  71. Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynecologic cancers. Semin Reprod Med. 2012;30:131–45.

    Article  PubMed  PubMed Central  Google Scholar 

  72. van Leeuwen FE, Klip H, Mooij TM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456–65.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995;274:1926–30.

    Article  CAS  PubMed  Google Scholar 

  74. Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2003;104:636–42.

    Article  CAS  PubMed  Google Scholar 

  75. Trabert B, Brinton LA, Anderson GL, et al. Circulating estrogens and postmenopausal ovarian cancer risk in the Women's Health Initiative observational study. Cancer Epidemiol Biomark Prev. 2016;25(4):648–56.

    Article  CAS  Google Scholar 

  76. Schock H, Surcel HM, Zeleniuch-Jacquotte A, et al. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer. 2014;21:831–44.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Fortner RT, Ose J, Merritt MA, et al. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort. Int J Cancer. 2015;137:1196–208.

    Article  CAS  PubMed  Google Scholar 

  78. Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol. 2010;171:45–53.

    Article  PubMed  Google Scholar 

  79. Ose J, Fortner RT, Rinaldi S, et al. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;136:399–410.

    Article  CAS  PubMed  Google Scholar 

  80. Rinaldi S, Dossus L, Lukanova A, et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol Biomark Prev. 2007;16:23–9.

    Article  CAS  Google Scholar 

  81. McSorley MA, Alberg AJ, Allen DS, et al. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int J Cancer. 2009;125:674–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–67.

    Article  CAS  PubMed  Google Scholar 

  83. Ose J, Fortner RT, Schock H, et al. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer. 2015;112:162–6.

    Article  CAS  PubMed  Google Scholar 

  84. Cardenas C, Alvero AB, Yun BS, et al. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer. 2016;23:R411–22.

    Article  PubMed  Google Scholar 

  85. Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer. 2015;22:R339–63.

    Article  CAS  PubMed  Google Scholar 

  86. Lacey JV Jr, Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003;98:814–21.

    Article  PubMed  Google Scholar 

  87. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer. 2003;103:705–8.

    Article  PubMed  Google Scholar 

  88. International Collaboration of Epidemiological Studies of Cervical C. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119:1108–24.

    Article  Google Scholar 

  89. Harris TG, Miller L, Kulasingam SL, et al. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol. 2009;200:489 e1–8.

    Article  Google Scholar 

  90. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.

    Article  CAS  PubMed  Google Scholar 

  91. Roura E, Travier N, Waterboer T, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One. 2016;11:e0147029.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Roberts JN, Kines RC, Katki HA, et al. Effect of pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst. 2011;103:737–43.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk: a meta-analysis. Eur J Cancer Prev. 2016;25:232–8.

    Article  CAS  PubMed  Google Scholar 

  94. Rinaldi S, Plummer M, Biessy C, et al. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomark Prev. 2011;20:2532–40.

    Article  CAS  Google Scholar 

  95. den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A. 2015;112:E3255–64.

    Article  Google Scholar 

  96. Coffey K, Gaitskell K, Beral V, et al. Past cervical intraepithelial neoplasia grade 3, obesity, and earlier menopause are associated with an increased risk of vulval cancer in postmenopausal women. Br J Cancer. 2016;115:599–606.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Newcomb PA, Weiss NS, Daling JR. Incidence of vulvar carcinoma in relation to menstrual, reproductive, and medical factors. J Natl Cancer Inst. 1984;73:391–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Rm SG/6E422, Bethesda, MD, 20892-9774, USA

    Louise A. Brinton Ph.D. & Britton Trabert Ph.D.

Authors
  1. Louise A. Brinton Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Britton Trabert Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louise A. Brinton Ph.D. .

Editor information

Editors and Affiliations

  1. Center for Science, Health and Society, Case Western Reserve University, Cleveland, Ohio, USA

    Nathan A. Berger

  2. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA

    Ann H. Klopp

  3. Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, Texas, USA

    Karen H. Lu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Brinton, L.A., Trabert, B. (2018). Role of Estrogen and Progesterone in Obesity Associated Gynecologic Cancers. In: Berger, N., Klopp, A., Lu, K. (eds) Focus on Gynecologic Malignancies. Energy Balance and Cancer, vol 13. Springer, Cham. https://doi.org/10.1007/978-3-319-63483-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63483-8_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63482-1

  • Online ISBN: 978-3-319-63483-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation